- Home
- SIGI vs IONS Comparison
SIGI vs IONS Comparison
Compare SIGI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGI
- IONS
- Stock Information
- Founded
- SIGI 1926
- IONS 1989
- Country
- SIGI United States
- IONS United States
- Employees
- SIGI N/A
- IONS N/A
- Industry
- SIGI Property-Casualty Insurers
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- SIGI Finance
- IONS Health Care
- Exchange
- SIGI Nasdaq
- IONS Nasdaq
- Market Cap
- SIGI 5.2B
- IONS 5.9B
- IPO Year
- SIGI N/A
- IONS 1991
- Fundamental
- Price
- SIGI $86.25
- IONS $39.62
- Analyst Decision
- SIGI Hold
- IONS Buy
- Analyst Count
- SIGI 8
- IONS 17
- Target Price
- SIGI $94.00
- IONS $57.59
- AVG Volume (30 Days)
- SIGI 378.2K
- IONS 1.7M
- Earning Date
- SIGI 07-17-2025
- IONS 07-31-2025
- Dividend Yield
- SIGI 1.77%
- IONS N/A
- EPS Growth
- SIGI N/A
- IONS N/A
- EPS
- SIGI 3.68
- IONS N/A
- Revenue
- SIGI $4,981,891,000.00
- IONS $717,253,000.00
- Revenue This Year
- SIGI $6.05
- IONS $7.98
- Revenue Next Year
- SIGI $7.43
- IONS $16.09
- P/E Ratio
- SIGI $23.37
- IONS N/A
- Revenue Growth
- SIGI 13.30
- IONS N/A
- 52 Week Low
- SIGI $78.13
- IONS $23.95
- 52 Week High
- SIGI $103.56
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- SIGI 47.69
- IONS 75.33
- Support Level
- SIGI $84.24
- IONS $34.78
- Resistance Level
- SIGI $87.88
- IONS $37.54
- Average True Range (ATR)
- SIGI 2.00
- IONS 1.19
- MACD
- SIGI 0.03
- IONS 0.33
- Stochastic Oscillator
- SIGI 39.43
- IONS 85.91
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.